BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 3, 2016
View Archived Issues
Phase I results on IONIS-DMPK-2.5R for the treatment of myotonic dystrophy type 1
Read More
Celgene announces product highlights of first quarter 2016
Read More
Novel gemcitabine prodrug shows improved antitumor efficacy
Read More
Further trials planned after phase Ia study of cyclopropavir in healthy subjects
Read More
Arenavirus entry inhibitor from Kineta shows preclinical efficacy
Read More
CHMP recommends E.U. approval of Gazyvaro for treatment of previously treated follicular lymphoma
Read More
Novel anti-CD352 ADC SGN-CD352A
Read More
Positive topline results from phase II/III trial of fasinumab in patients with osteoarthritis pain
Read More
EMA's CHMP recommends approval of HyQvia in pediatric patients
Read More
FDA clears TRACT Therapeutics's phase II study of Treg therapy for kidney transplant rejection
Read More
Tobira Therapeutics interim results from ORION study of cenicriviroc
Read More
AstraZeneca completes acquisition of Takeda's core respiratory business
Read More
FDA awards new orphan drug designations to Kite Pharma's KTE-C19
Read More
Prosetta Biosciences enters agreement with Takeda to develop drugs for CNS disorders
Read More
Kamada receives two milestone payments from AAT agreements
Read More
Oncodesign enters into strategic partnership with Ipsen in oncology
Read More
Celsion reports data from OVATION study of GEN-1
Read More
Enrollment to continue in Protalex's phase Ib study of PRTX-100
Read More
EMA committee recommends approval of Ongentys
Read More
Progenics Pharmaceuticals licenses technology to Bayer
Read More
Encore Vision's phase I-II study of EV-06 meets primary endpoints
Read More
Rigel identifies MerTK inhibitors for treating cancer
Read More
FDA approves Eisai's Fycompa CIII oral suspension
Read More
Update on Acorda's acquisition of Biotie
Read More
Oligomerix receives a grant for its Alzheimer's drug discovery program from the NIH
Read More